Publisher
Springer International Publishing
Reference63 articles.
1. Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F, Ruiz-Cabello F (1998) Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 47:113–120
2. Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen TZ, Rosenkrantz Hölmich L, Westergren Hendel H, Met O, Hald AM, Thor Straten P, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res 22(15):3734–3745
3. Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL (2014) MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20:6034–6044
4. Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727–1733
5. Aptsiauri N, Garcia-Lora A, Garrido F (2014) Chapter 5: “Hard” and “Soft” loss of MHC class I expression in cancer cells. In: Rees B (ed) Tumour immunology & immunotherapy. Oxford University Press, pp 63–78
Cited by
34 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献